



INCLUDES
CD-ROM

Second Edition

Handbook of Process Chromatography

Development, Manufacturing,
Validation and Economics



Lars Hagel, Günter Jagschies and
Gail Sofer



Handbook of Process Chromatography

Development, Manufacturing,
Validation and Economics

Second Edition

Lars Hagel

GE Healthcare, Uppsala, Sweden

Günter Jagschies

GE Healthcare, Uppsala, Sweden

AND

Gail Sofer

GE Healthcare, Piscataway, NJ, USA



ELSEVIER

Amsterdam • Boston • Heidelberg • London • New York • Oxford
Paris • San Diego • San Francisco • Singapore • Sydney • Tokyo

Academic Press is an imprint of Elsevier



ACADEMIC
PRESS

Academic Press is an imprint of Elsevier
84 Theobald's Road, London WC1X 8RR, UK
Radarweg 29, PO Box 211, 1000 AE Amsterdam, The Netherlands
Linacre House, Jordan Hill, Oxford OX2 8DP, UK
30 Corporate Drive, Suite 400, Burlington, MA 01803, USA
525 B Street, Suite 1900, San Diego, CA 92101-4495, USA

First edition 1997. Published by Academic Press under ISBN 978-0-12-654266-0
Second edition 2008

Copyright © 2008 Elsevier Ltd. All rights reserved

No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the publisher

Permissions may be sought directly from Elsevier's Science & Technology Rights Department in Oxford, UK: phone (+44) (0) 1865 843830; fax (+44) (0) 1865 853333; email: permissions@elsevier.com. Alternatively you can submit your request online by visiting the Elsevier web site at <http://www.elsevier.com/locate/permissions>, and selecting *Obtaining permission to use Elsevier material*

Notice

No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made

ISBN: 978-0-12-374023-6

ISBN: 978-0-12-374187-5 (inserted CD ROM only)

For information on all Academic Press publications
visit our website at books.elsevier.com

Printed and bound in The Netherlands

08 09 10 11 12 10 9 8 7 6 5 4 3 2 1

Working together to grow
libraries in developing countries

www.elsevier.com | www.bookaid.org | www.sabre.org

ELSEVIER

BOOK AID
International

Sabre Foundation

Handbook of Process Chromatography

Development, Manufacturing,
Validation and Economics

Second Edition

Preface

Biotherapeutics have become the main drivers for the pipeline of the pharmaceutical industry, and carry hope for millions of patients for a better life with, or even cure from, diseases for which there are no existing effective treatments. This group of medicines includes, but is not limited to, protein and nucleic acid-based therapeutics as well as different classes of vaccines and gene therapy treatments. Today, there are a few hundred licensed biotherapeutics produced from genetically engineered cells and over a thousand are in pre-clinical and clinical studies.

Process chromatography provides companies developing or manufacturing biological pharmaceuticals tools to fulfil high requirements on safety and quality of active ingredients. This book discusses process chromatography tools and their capabilities; and it does so with all the main interrelations between different phases of manufacturing kept in mind.

Since the first edition of this book, the field has matured significantly and has seen a number of important new aspects in business strategies, manufacturing framework and use of new technology. Emphasis has shifted away from the focus on individual steps and their technical performance to a more comprehensive process operational view. Statistical tools are now used to establish robust operating parameters, and analytical methods have been significantly improved.

In this book, we take a holistic approach to describe purification processes by considering the biopharmaceutical industry and its needs, the types of products and the sources from which they are produced, other technologies that are used prior to purification and some other technologies, such as filtration that complement chromatography, which is still the workhorse of downstream purification.

In Chapter 1, we address the state of the biopharmaceutical industry today. This sets the stage for the subsequent chapters. Much has changed. For example, the whole concept of follow-on products, generic approaches and platform technologies were not even topics of interest when the first edition of this book was published.

Chapter 2 describes process capability from the perspective of several functional departments, the market needs for biopharmaceuticals and some production setups for manufacturing at different scales during the various stages of development and production. The ability of mammalian cell and microbial substrates to meet the future market demands is explored, and the use of multi-product facilities described.

Chapter 3 presents process design concepts that enable development of a process suitable for manufacturing biotherapeutics. We discuss, among other topics, the importance of risk assessments, the design of a logical purification strategy and characterization studies. Expression systems used to produce biopharmaceuticals, with an emphasis on the most commonly used hosts, *E. coli* and CHO, are discussed in terms of productivity and types of products made today.

Separation technologies that are discussed in Chapter 4 include both chromatography and filtration. An overview of currently used recovery steps is followed by a discussion on basic chromatography techniques and their optimization and scale-up.

In Chapter 5, in-process and final product analytical methods are presented. Specific analytical tools applied to monoclonal antibodies and nucleic acid products, such as DNA plasmids, are described. Process analytical technologies (PAT), method validation, setting specifications and the use of standards are also addressed.

Chapter 6 addresses the always-important issues of cleaning and sanitization of chromatography resins, reusable filters and equipment. This chapter is followed by validation (Chapter 7), which includes cleaning validation for chromatography columns.

An appendix to the Chapter 7 provides a summary of activities from pre-clinical to post-licensure for biopharmaceutical production from genetically engineered mammalian cells. Current validation trends, which are discussed, may influence future validation costs.

Economy of production has become more and more important since our previous edition. The economics is addressed in Chapter 8.

Chapter 9 on basic properties of biological molecules has been updated to include viral and DNA-based therapeutics and highlights properties of some important type of biopharmaceuticals.

Chapter 10 discusses optimization of separation processes based on well-established chromatography theory. Influence of experimental parameters may be simulated with the software tutorials supplied on a CD-ROM.

Our final two chapters address chromatographic equipment and column packing. New equipment designs, improved automation and pack-in-place columns are discussed.

Appendices with detailed references for nomenclature of liquid chromatography, reduced numbers used in process engineering, validation activities during development and the simulation tutorial complete the content of the second edition of *Handbook of Process Chromatography*.

We hope you will find the content of this book helpful for your daily work and as your reference in the coming decade.

Uppsala, Sweden and Warren, NJ, USA
Lars Hagel, Günter Jagschies and Gail Sofer

Acknowledgements

We would like to acknowledge the invaluable support and most helpful reviews and comments from a number of colleagues who have generously contributed to the first and the second editions of *Handbook of Process Chromatography*:

Mattias Ahnfelt	Hans. J. Johansson
Michael Berg	Brian Kelley
Andreas Bergström	Karol Lacki
Wolfgang Berthold	Athanasios I. Liapis
Greg Blank	Raf Lemmens
Enrique Carredano	Gunnar Malmquist
Steven Cramer	Lars-Erik Nyström
Hedvig Englund	Craig Robinson
Kjell Eriksson	Lena Sandberg
Klaus Gebauer	Lisa Stack
Ann-Christine Gellerbring	Joakim Svensson
Eric Grund	Jörg Thömmes
Felicia Henderson	Joachim Walter
Sybill Herzer	Yujing Yang
Rolf Hjorth	
Hamid Housmand	

Lars Hagel
Günter Jagschies
Gail Sofer

Trademark statement

AxiChrom, GammaBind, Sepharose, Superdex, Sephacryl, Sephadex, Superose, Mono Q, Mono S, SOURCE, ÄKTAexplorer, RESOURCE, Capto, MabSelect, MabSelect Xtra and MabSelect SuRe are trademarks owned by GE Healthcare companies. GE monogram is a trademark owned by General Electric Company. Biacore is a registered trademark of Biacore AB.

Threshold is a registered trademark of Molecular Devices Corporation.

Santoprene is a trademark of Exxon Mobile Corp. Viton is a registered trademark of DuPont Performance Elastomers. Kynar is a registered trademark of Arkema Inc.

All trademarks mentioned in the text are the property of the respective owners.

Contents

<i>Preface</i>	xv
<i>Acknowledgements</i>	xvii

1 Biopharmaceuticals Today	1
1.1 Industrial Context	1
1.2 Overview of Biopharmaceutical History	2
1.2.1 Protein drugs	2
1.2.2 Vaccines	4
1.3 Biopharma Business Environment	6
1.3.1 Biopharma pipeline: the promise	6
1.3.2 Launched biopharmaceuticals: delivering on promises	7
1.3.3 Chromatography products used for making biopharmaceuticals	9
1.4 Key Business Issues	10
1.4.1 Prime challenge, time and cost of new drug development	10
1.4.2 Other significant business challenges	11
1.4.3 Biosafety and general drug safety issues	14
1.4.4 Regulatory issues	15
1.5 Process Chromatography within an Industrial Context	16
1.5.1 High-level managerial strategies	16
1.5.2 Development project throughput	17
1.5.3 Manufacturing strategies	17
1.5.4 Technology platforms	18
1.5.5 Constraints on technology and product choices	19
1.6 Summary	20
References	21
2 Process Capability and Production Scenarios	23
2.1 Process Capability	23
2.1.1 The process scientist's perspective	23
2.1.2 The production manager's perspective	23
2.1.3 How much product needs to be made?	25
2.2 Production Setups	27
2.2.1 Production setup for several hundred grams up to ten-kilogram scale	30
2.2.2 Production setup for several tens of kilograms up to multi-ton scale	30
Upstream process	30
Downstream process	33
2.2.3 Multi-product facilities	36

2.3	Process Capability Conclusions	37
	References	39
3	Process-Design Concepts	41
3.1	Typical Process Design for Biopharmaceuticals	41
3.2	Management Framework for Process Design	43
3.2.1	Defining structure and workflow for process design	43
3.3	Production Cells and Typical Product Characteristics	47
3.3.1	Production cells and their selection	47
	Mammalian cells	49
	Escherichia coli	49
	Yeast	50
	Filamentous fungi	50
	Insect cells	50
	Transgenic plants	51
	Transgenic animals	51
3.3.2	Typical impurity profiles	51
	Product-related impurities	51
	Process-related impurities	52
3.3.3	Knowing the target molecule and its stability window	54
3.4	Risk Analysis and Risk Mitigation	55
3.4.1	Categories of risks, prioritization and mitigation strategies	56
3.4.2	Mitigation of safety risks	58
3.5	Downstream Processing	60
3.5.1	Recovery process	60
3.5.2	Purification process	61
	Selection of industrial raw materials	61
3.5.3	The Capture, purification, polishing (CPP) concept	63
	Capture stage	66
	Purification stage	66
	Polishing stage	67
3.5.4	Process integration, combining steps for an efficient process	67
3.6	Selected Downstream Processing Platform Examples	69
3.6.1	Monoclonal antibodies	69
3.6.2	Plasmid DNA (pDNA)	71
3.7	Characterizing the Process, Process Understanding	73
3.7.1	Design space concept, ICH Q8	73
3.7.2	Statistical design of experiments (DoE)	73
3.7.3	Process characterization	77
	References	78
4	Separation Technologies	81
4.1	Introduction	81
4.2	Recovery	81
4.2.1	Centrifugation	82
4.2.2	Filtration	83

4.2.3	Other techniques	84
	Fluidized beds	85
	Protein crystallization	85
4.3	Purification.	86
4.3.1	Design principles	86
4.3.2	Chromatography resins	86
4.3.3	Selectivity and productivity of some popular chromatographic techniques.	88
	Size exclusion chromatography	92
	Ion exchange chromatography	96
	Reversed phase chromatography	103
	Hydrophobic interaction chromatography	106
	Affinity chromatography	109
	Other modes of chromatography	113
4.3.4	Scale-up of chromatographic purifications.	114
	Guidelines	114
	System factors	116
	Examples of scale-up.	116
	Non-chromatographic scale factors	118
4.3.5	Ultrafiltration	118
	Optimization of ultrafiltration	119
4.3.6	Virus filters	120
4.4	Equipment	121
4.5	Selecting Tools from R&D to Production	122
	References	122
5	Analysis	127
5.1	Introduction	127
5.2	Proteins	127
5.2.1	Identity	127
5.2.2	Purity	128
	Structural analysis	129
	Process impurities	130
	Contaminants	132
5.2.3	Quantity	133
5.2.4	Potency	134
5.2.5	Stability	134
5.2.6	Assays for monoclonal antibodies	135
5.3	Nucleic Acid Products	136
5.3.1	Identity	136
5.3.2	Purity	136
	Process impurities	137
	Contaminants	138
5.3.3	Quantity	139
5.3.4	Potency	139
5.3.5	Stability	139
5.4	Comparability	140
5.5	Setting Specifications and Reference Standards	140

5.6	Method Validation	141
5.7	Process Analytical Technologies (PAT).....	141
	References	142
6	Cleaning and Sanitization.....	147
6.1	Introduction	147
6.2	Cleaning.....	147
6.2.1	Resins.....	147
6.2.2	Filter media	151
6.2.3	Equipment	152
6.3	Decontamination of Transmissible Spongiform Encephalopathy Agents	153
6.3.1	Resins and filter media	153
6.3.2	Equipment	154
6.4	Sanitization	154
6.4.1	Resins.....	155
6.4.2	Filter media	157
6.4.3	Equipment	157
	References	158
7	Validation	161
7.1	Introduction	161
7.1.1	Validation terminology	161
7.2	What to do When?	162
7.2.1	Toxicology studies	163
7.2.2	Human clinical trials.....	163
7.3	Validation of Downstream Processes	164
7.3.1	General considerations	164
7.3.2	Raw materials and process tools	165
	Acceptance criteria for chromatography resins.....	165
7.3.3	Equipment	168
	Equipment qualification.....	168
	Installation qualification	169
	Operational qualification	170
	Automated equipment qualification	170
	Column packing and qualification	172
7.3.4	Process validation	172
	Storage	174
	Leachables.....	175
	Cleaning and sanitization validation.....	177
	Resin and membrane lifetime	180
	Small and manufacturing scales.....	182
	Clearance studies.....	184
7.4	Making Changes	184
7.5	Summary	185
	Acknowledgements	185
	References	186

8	Economics	189
8.1	Economics: An Educational Excursion	190
8.1.1	Costs as seen from a corporate level	190
8.1.2	Costs as seen from a manufacturing management level	192
8.1.3	Costs as seen with an interesting novel technology in mind	196
8.2	LEAN Manufacturing, Removal of Unproductive Activities	197
8.3	Cost Model: Monoclonal Antibody Downstream Process	199
8.4	Cost Improvement Options	202
8.4.1	Facility utilization	202
8.4.2	Cell culture: product titer and culture time	204
8.4.3	Process yield	206
8.4.4	Use of the latest resin technology	208
8.4.5	Re-use strategies	209
8.4.6	Buffer consumption and cleaning buffers	211
8.4.7	Exchange of one step against a cheaper one	212
8.5	Impact from R&D, Platform Strategies and Technology Outlook	214
8.6	Conclusions, the Improvement Hierarchy	215
	References	216
9	Basic Properties of Peptides, Proteins, Nucleic Acids and Virus Particles	219
9.1	Introduction	219
9.2	Peptides	219
9.2.1	Amino acid composition	220
9.2.2	Structure of peptides	221
9.2.3	Surface properties of peptides	221
9.2.4	Characterization methods of peptides	221
9.3	Proteins	222
9.3.1	Structure of proteins	222
9.3.2	Surface properties of proteins	223
9.3.3	Characterization methods of proteins	226
9.3.4	Properties of human antibodies and antibody fragments	226
9.4	Nucleic Acids	228
9.4.1	Basic structure of DNA and RNA	228
9.4.2	Surface properties of nucleic acids	229
9.4.3	Characterization methods of nucleic acids	230
9.5	Viruses	231
9.5.1	Structure of virus particles	231
9.5.2	Surface properties of virus particles	232
9.5.3	Characterization methods for virus particles	232
	References	234
10	Optimization of Chromatographic Separations	237
10.1	Introduction	237
10.2	Basic Relationships	238
10.2.1	Resolution	238
10.2.2	Retention	239

10.2.3	Zone broadening	240
10.2.4	Mass transfer	243
10.2.5	Flow resistance of packed beds	243
10.3	Purification Principles	245
10.3.1	Gel filtration/size exclusion chromatography, SEC	245
	Retention in SEC	245
	Zone broadening in SEC	247
	Resolution in SEC	248
	Influence of experimental parameters in SEC	248
10.3.2	Ion exchange chromatography, IEC	252
	Retention in IEC	252
	Zone broadening in IEC	253
	Resolution in IEC	254
	Influence of experimental parameters in IEC	254
10.3.3	Reversed-phase chromatography, RPC	258
	Retention in RPC	258
	Zone broadening in RPC	258
	Resolution in RPC	259
	Influence of experimental parameters in RPC	259
10.3.4	Hydrophobic interaction chromatography, HIC	262
	Retention in HIC	262
	Zone broadening in HIC	262
	Resolution in HIC	263
	Influence of experimental parameters in HIC	263
10.3.5	Affinity chromatography, AC	265
	Retention in AC	265
	Zone broadening in AC	266
	Resolution in AC	266
	Influence of experimental parameters in AC	266
10.3.6	Other modes of chromatography	267
10.4	Adsorption	267
10.4.1	Adsorption isotherms	269
	Linear chromatography	271
	Non-linear chromatography	271
10.5	Elution Modes	272
10.5.1	Frontal chromatography	272
10.5.2	Elution chromatography	272
10.5.3	Displacement chromatography	273
10.5.4	Sample displacement	273
10.6	Bed Configuration	274
10.6.1	Packed beds	274
10.6.2	Fluidized beds	274
10.6.3	Moving beds	275
10.7	Experimental Determination of Basic Parameters	276
10.7.1	Retention	276
	Retention volume, V_R	276
	Mobile-phase volume, V_M	278
	Mobile-phase composition at elution	278
10.7.2	Zone broadening	278
	Peak width and plate number	278

	Residence time distribution, RDT	279
	Vessel dispersion number	280
10.7.3	Resolution	281
10.7.4	Mass transfer	281
10.7.5	Capacity	281
	Ionic capacity	281
	Solute capacity	281
10.8	Modelling of Chromatographic Purifications	284
10.8.1	Mass transfer in chromatography	285
	Mass transfer in the mobile phase	286
	Mass transfer in the stationary phase	286
10.8.2	Models for mass transfer	289
	Rate model (mass balance model)	289
	Plate model	290
10.8.3	Computer modelling of chromatographic purifications	291
10.9	Simulation of Separations	291
10.9.1	Calculation of process economy	291
10.9.2	Simulations using the supplied software	292
	References	292

11 Equipment **299**

11.1	Guidelines for Selecting Pilot Plant and Production Chromatography Equipment	299
11.1.1	Dimensioning data	299
11.1.2	Functional specifications	300
11.1.3	Chemical specifications	300
11.1.4	Pressure specifications	303
11.1.5	Hygienic design	304
11.1.6	Zone spreading	304
11.1.7	Documentation	306
11.2	Selection of Components	306
11.2.1	Columns	306
11.2.2	Valves	309
11.2.3	Pumps	310
	Cleaning	310
	Chemical resistance	310
	Pressure/flow rate	311
	Temperature tolerance	311
	Shearing	311
	Speed control	311
	Pulsations	312
11.2.4	Monitors, meters and sensors	312
	UV monitors	312
	Conductivity monitors	312
	pH monitors	313
	Flow meters	313
	Air sensors	314

11.2.5	Tubing or piping	314
11.2.6	Fraction collectors	314
11.3.	Automation	314
11.3.1	Advantages of automation	315
11.3.2	Control systems	315
	Dedicated control system	315
	Programmable logical controller system	315
	Personal computer system	316
	Distributed control systems and networking	316
11.3.3	Hardware and software specifications	316
References		319
12	Column Packing	321
12.1	Introduction	321
12.2	Theory	321
12.3	Preparation of Column and System.	323
12.4	Packing the Column	324
12.4.1	Packing solution	324
12.4.2	Preparation of the slurry	324
12.4.3	Determination of packing parameters	325
12.4.4	Packing methods	325
12.5	Evaluating Column Packing Quality	326
12.5.1	The step method	326
12.5.2	The pulse method	327
12.6	Scale Up.	329
References		330
Appendix A:	Symbols and Definitions in Liquid Chromatography	331
A.1	Introduction	331
A.2	Symbols Used in Liquid Chromatography	331
A.3	Definitions of Chromatographic Parameters and Equations.	333
References		336
Appendix B:	Dimensionless Numbers	337
B.1	Introduction	337
References		339
Appendix C:	Activities for Biopharmaceutical Production from Genetically Engineered Mammalian Cells	341
C.1	Introduction	341
C.2	Activities Chart from Toxicology to License Application	341

Appendix D: Simulations Using the Supplied Software. 345

 D.1 Introduction 345

 D.2 How to Use the Software? 345

 D.3 Pressure Drop. 346

 D.3.1 Calculations 346

 D.4 Sample Volume 347

 D.4.1 Calculations 347

 D.5 Resolution in SEC 348

 D.5.1 Calculations 348

 D.6 Resolution in IEC, RPC and HIC 348

 D.6.1 Calculations 348

 D.7 Isocratic Separation 349

 D.7.1 Entry of parameters. 349

 D.7.2 Calculations 349

 D.8 Yield and Purity 350

 D.8.1 Calculations 350

 D.9 Langmuir Isotherm. 350

 D.9.1 Calculations 351

 D.10 About this Software 351

Subject Index. 353

Biopharmaceuticals Today

1.1 INDUSTRIAL CONTEXT

In our introduction to the 1st edition of this book in 1997 we wrote: ‘In the rush to get a product to market, process optimization and validation are often sacrificed’, which indicated a certain lack of maturity in the biopharmaceutical field at that time. Those days are gone. A significant portion of biopharmaceutical drug development is now performed by experienced big pharma and a small number of established biopharma companies. In addition, there are hundreds of small companies and start-up institutions without sufficient competence to bring novel biopharmaceuticals all the way to market; but today, even these organizations have full access to the required expertise from contract manufacturing and clinical research organizations.

Consequently, the routines followed by this industry have matured. Where there was once mere science and many remaining unknown issues for manufacturing protein-based drugs, there are now sets of tools, the challenges are well understood and relevant information is in the public domain. Process chromatography, the main topic of this handbook, is one of the most important tools due to its close relation to end-product quality and safety. Well-managed platforms with overall workflow and specific methods are being established for every aspect of process development, analytical tasks and even regulatory procedures. These platforms are upgraded in a carefully controlled fashion following progress in science and applicable technology. Knowledge gaps are closing rapidly.

In addition to biochemical and biological science, process engineering is beginning to dominate the field as protein production loses most of the ‘mysteries of biology’ and moves towards predictable and controllable production operations. This is not, yet, the situation with emerging gene and cell-based candidate therapeutic agents, where the uncertainties and inexperience reflect the situation that existed for protein drugs just two decades ago. The design of work strategies and methods for these novel medicines still constitutes a major challenge for their developers, as well as for regulators evaluating the associated risks.

The following sections in this chapter provide a brief history and describe the current biopharmaceutical business. Our description is qualitative, i.e. where there are business-related numbers, they are merely intended to create a snapshot that may help to illustrate or exemplify our points. We are perfectly aware that this industry is moving too fast to